Immuno-oncology drug developer Oxis International has agreed to buy Georgetown Translational Pharmaceuticals (GTP) in exchange of 33% of its outstanding shares.

The acquisition will add a class of close-to-market central nervous systems (CNS) products to Oxis, and accelerate the clinical development of cancer and neurologic disease-related treatments.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The merger also includes a $125m upfront payment from Allergan, a company owned by the newly appointed CEO of Oxis. Allergan will also provide potential regulatory and commercial milestones of up to $875m.

“The acquirer plans to raise $26.3m through a private placement of shares to partly fund the acquisition.”

Hangzhou Tianmushan Pharmaceutical intends to acquire an AnhuiIn-based pharmaceutical company in a $52.7m deal.

The acquirer plans to raise $26.3m through a private placement of shares to partly fund the acquisition.

Biopharmaceutical company Sinovac Biotech will be bought by Shandong Sinobioway Biomedicine for a cash consideration of $8 a share.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In a $2m deal, Zhejiang Jingxin Pharmaceutical will purchase an up to 25% stake in Spes Pharmaceuticals.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now